ArticleHemaSphere2022
Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- VEXAS syndrome as an underlying cause of disease in patients with Sweet syndrome.JAAD case reports · 2026Article
- VEXAS Syndrome: Clinical Features, Hematologic Involvement, and Clinical Outcomes of Current and Emerging Therapies.Hematology reports · 2026Review
- Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review.EClinicalMedicine · 2025Review
- VEXAS, Chediak-Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator?Cellular & molecular biology letters · 2025Review
- Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.Annals of hematology · 2024Review
- Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT.Blood advances · 2024Article
- Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.Nature communications · 2024Article
- Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome.Rheumatology advances in practice · 2024Article
- Review
- Case report: VEXAS syndrome: an atypical indolent presentation as sacroiliitis with molecular response to azacitidine.Frontiers in immunology · 2024Article
- VEXAS Syndrome-Review.Global medical genetics · 2023Review
- VEXAS syndrome: a diagnostic puzzle.RMD open · 2023Article
- Article
- Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome.HemaSphere · 2023Article
- Neutrophilic and eosinophilic dermatoses associated with hematological malignancy.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.